Chronic Hepatitis B (CHB) Market By Drug Class (Antivirals, Immune Modulators), By Gender (Male, Female), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031

Chronic Hepatitis B (CHB) Market

Hepatitis B is a viral infection that causes liver inflammation and damage. Inflammation is swelling that occurs when tissues of the body become injured or infected. Inflammation can damage organs. Chronic hepatitis B is a long-lasting infection. According to National Institutes of Health (NIH), about 90% of infants infected with hepatitis B develop a chronic infection. About 25 to 50% of children infected between the ages of 1 and 5 years develop chronic infections. However, only about 5% of people first infected as adults develop chronic hepatitis B.

The surge in the prevalence of hepatitis B and improvements in healthcare infrastructure drive the growth of the Chronic Hepatitis B Market Size. For instance, in April 2022, according to Bristol Myers & Squibb, each year, nearly 1 million people worldwide died due to hepatitis B or hepatitis c. In addition, rise in awareness about hepatitis infection and advancements in hepatitis treatment boost the expansion of the Chronic Hepatitis B Industry.

The strict government regulations on blood transfusion and blood banks contribute to the growth of the Chronic Hepatitis B Market Size. The World Health Organization (WHO) recommends that all blood donations should be screened for infections prior to use. Screening for HIV, hepatitis B, hepatitis c, and syphilis should be mandatory. and initiatives taken by the government and non-government organizations propel the growth of the Chronic Hepatitis B Market Size.

Furthermore, Chronic Hepatitis B Market Trends that drive the growth of the chronic hepatitis B market include R&D for the development of chronic hepatitis B, an increase in drug class approvals, and new product launches in the market. In addition, advancements in the diagnosis of hepatitis B propel the growth of the market. For instance, in May 2022, Abbott, a leading pharmaceutical company, announced the launch of HBsAg Next Qualitative Assay for early detection of the Hepatitis B virus (HBV) in India. Early identification of HBV infections not only helps in preventing or delaying the progression of advanced liver diseases but also reduces the risk of transmission. Furthermore, the rise in healthcare expenditure and improvements in healthcare facilities in developing nations contribute to the growth of the Chronic Hepatitis B Industry.

The chronic hepatitis B market is segmented into drug class, gender, distribution channel, and region.

Based on the drug class segment, the market is divided into antivirals and immune modulators. The antivirals segment dominated the Chronic Hepatitis B Market Share in 2021, and this trend is expected to continue during the Chronic Hepatitis B Market Forecast period, owing to the increase in the prevalence of hepatitis B.

Based on gender segment, the market is categorized into male and female. The male segment dominated the market in 2021, and this trend is expected to continue during the forecast period, owing to the high prevalence rate of male and an increase in blood transfusion rate.

Depending on the distribution channel segment, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. The drug stores & retail pharmacies segment dominated the market in 2021, and this trend is expected to continue during the forecast period, owing to an increase in healthcare expenditure and a rise in the number of drug stores & retail pharmacies.

North America accounted for a majority of the global chronic hepatitis B market share in 2021 and is anticipated to remain dominant during the forecast period. This is attributed to the rising prevalence of hepatitis B, the well-established healthcare infrastructure, and the presence of key players in the region. Asia-Pacific is anticipated to witness lucrative growth during the Chronic Hepatitis B Market Analysis period owing to an increase in the number of blood banks, growth in the geriatric population, and a high population base.

Key findings of the study

By drug class, the antivirals segment was the highest contributor to the Chronic Hepatitis B (CHB) Market in 2021.

By gender, the male segment was the highest contributor to the Chronic Hepatitis B (CHB) Market in 2021.

By distribution channel, the drug stores & retail pharmacies segment was the highest contributor to the market in 2021.

Region wise, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period

Overview

The global chronic hepatitis B market was valued at $4,589.8 million in 2021 and is projected to reach $6,213.15 million by 2031, registering a CAGR of 3.0% from 2022 to 2031.  Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease. Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). Hepatitis B can cause chronic infection and increases the risk of death from cirrhosis and liver cancer.

The increase in rate of hepatitis B and rise in awareness about hepatitis B drive the growth of the market. For instance, according to a report of World Health Organization (WHO) published in June 2022, globally, an estimated 296 million people were living with chronic hepatitis B infection in 2019, with 1.5 million new infections each year. Thus, increase in prevalence of hepatitis B globally boosts the growth of the market.

In addition, factors such as increase in blood donation and rise in blood transfusion rate foster the growth of the market. The blood transfusion is a leading cause of hepatitis B virus transmission. For instance, as per the report of World Health Organization (WHO) published in May 2022, about 118.54 million blood donations are made worldwide. About 40% of these are collected in high-income countries. The World Health Organization (WHO) recommends that all blood donations should be screened for infections prior to use. Screening for HIV, hepatitis B, hepatitis c, and syphilis should be mandatory.

Moreover, increase in R&D activities for development of novel chronic hepatitis B treatment, rise in the U.S. food & drug administration (FDA) approvals and novel product launch in the market by key players boost the market growth. For instance, in June 2022, glaxosmithkline (GSK), a science-led global healthcare company, announced the interim results from the B-Clear phase IIb trial showing that bepirovirsen, an investigational antisense oligonucleotide treatment for hepatitis B, reduced levels of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA after 24 weeks’ treatment in people with chronic hepatitis B (CHB). Furthermore, advancements in hepatitis B treatment and rise in diagnosis rate further contribute toward the market growth. However, high cost of chronic hepatitis B drugs is projected to hinder the growth of the market.

The chronic hepatitis B market is segmented on the basis of drug class, gender, distribution channel, and region. By drug class, the market is fragmented into antivirals, and immune modulators. By gender, the market is classified into male, and female. The male segment is further divided into adult and geriatric. The female segment is further divided into adult and geriatric. By distribution channel, the market is categorized into hospital pharmacies, drug stores & retail pharmacies, and online providers. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include Biocon Inc, Cipla Limited, Dr. Reddy's Laboratories, Gilead Sciences, Inc., Novartis AG, Reliance Life Sciences, Sun Pharmaceutical Industries Limited, Teva pharmaceuticals, Viatris Inc and Zydus Cadila.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the chronic hepatitis b (chb) market analysis from 2021 to 2031 to identify the prevailing chronic hepatitis b (chb) market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the chronic hepatitis b (chb) market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global chronic hepatitis b (chb) market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ Cipla Lt

Scope of Chronic Hepatitis B (CHB) Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

4.1 Overview

4.1.1 Market size and forecast

4.2 Antivirals

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market analysis by country

4.3 Immune Modulators

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 Male

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market analysis by country

5.2.4 Male Chronic Hepatitis B (CHB) Market by Age Group

5.2.4.1 Adult Market size and forecast, by region

5.2.4.2 Geriartic Market size and forecast, by region

5.3 Female

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market analysis by country

5.3.4 Female Chronic Hepatitis B (CHB) Market by Age Group

5.3.4.1 Adult Market size and forecast, by region

5.3.4.2 Geriartic Market size and forecast, by region

6.1 Overview

6.1.1 Market size and forecast

6.2 Hospital Pharmacies

6.2.1 Key market trends, growth factors and opportunities

6.2.2 Market size and forecast, by region

6.2.3 Market analysis by country

6.3 Drug Stores and Retail Pharmacies

6.3.1 Key market trends, growth factors and opportunities

6.3.2 Market size and forecast, by region

6.3.3 Market analysis by country

6.4 Online Providers

6.4.1 Key market trends, growth factors and opportunities

6.4.2 Market size and forecast, by region

6.4.3 Market analysis by country

7.1 Overview

7.1.1 Market size and forecast

7.2 North America

7.2.1 Key trends and opportunities

7.2.2 North America Market size and forecast, by Drug Class

7.2.3 North America Market size and forecast, by Gender

7.2.3.1 North America Male Chronic Hepatitis B (CHB) Market by Age Group

7.2.3.2 North America Female Chronic Hepatitis B (CHB) Market by Age Group

7.2.4 North America Market size and forecast, by Distribution Channel

7.2.5 North America Market size and forecast, by country

7.2.5.1 U.S.

7.2.5.1.1 Market size and forecast, by Drug Class

7.2.5.1.2 Market size and forecast, by Gender

7.2.5.1.3 Market size and forecast, by Distribution Channel

7.2.5.2 Canada

7.2.5.2.1 Market size and forecast, by Drug Class

7.2.5.2.2 Market size and forecast, by Gender

7.2.5.2.3 Market size and forecast, by Distribution Channel

7.2.5.3 Mexico

7.2.5.3.1 Market size and forecast, by Drug Class

7.2.5.3.2 Market size and forecast, by Gender

7.2.5.3.3 Market size and forecast, by Distribution Channel

7.3 Europe

7.3.1 Key trends and opportunities

7.3.2 Europe Market size and forecast, by Drug Class

7.3.3 Europe Market size and forecast, by Gender

7.3.3.1 Europe Male Chronic Hepatitis B (CHB) Market by Age Group

7.3.3.2 Europe Female Chronic Hepatitis B (CHB) Market by Age Group

7.3.4 Europe Market size and forecast, by Distribution Channel

7.3.5 Europe Market size and forecast, by country

7.3.5.1 Germany

7.3.5.1.1 Market size and forecast, by Drug Class

7.3.5.1.2 Market size and forecast, by Gender

7.3.5.1.3 Market size and forecast, by Distribution Channel

7.3.5.2 France

7.3.5.2.1 Market size and forecast, by Drug Class

7.3.5.2.2 Market size and forecast, by Gender

7.3.5.2.3 Market size and forecast, by Distribution Channel

7.3.5.3 UK

7.3.5.3.1 Market size and forecast, by Drug Class

7.3.5.3.2 Market size and forecast, by Gender

7.3.5.3.3 Market size and forecast, by Distribution Channel

7.3.5.4 Italy

7.3.5.4.1 Market size and forecast, by Drug Class

7.3.5.4.2 Market size and forecast, by Gender

7.3.5.4.3 Market size and forecast, by Distribution Channel

7.3.5.5 Spain

7.3.5.5.1 Market size and forecast, by Drug Class

7.3.5.5.2 Market size and forecast, by Gender

7.3.5.5.3 Market size and forecast, by Distribution Channel

7.3.5.6 Rest of Europe

7.3.5.6.1 Market size and forecast, by Drug Class

7.3.5.6.2 Market size and forecast, by Gender

7.3.5.6.3 Market size and forecast, by Distribution Channel

7.4 Asia-Pacific

7.4.1 Key trends and opportunities

7.4.2 Asia-Pacific Market size and forecast, by Drug Class

7.4.3 Asia-Pacific Market size and forecast, by Gender

7.4.3.1 Asia-Pacific Male Chronic Hepatitis B (CHB) Market by Age Group

7.4.3.2 Asia-Pacific Female Chronic Hepatitis B (CHB) Market by Age Group

7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel

7.4.5 Asia-Pacific Market size and forecast, by country

7.4.5.1 Japan

7.4.5.1.1 Market size and forecast, by Drug Class

7.4.5.1.2 Market size and forecast, by Gender

7.4.5.1.3 Market size and forecast, by Distribution Channel

7.4.5.2 China

7.4.5.2.1 Market size and forecast, by Drug Class

7.4.5.2.2 Market size and forecast, by Gender

7.4.5.2.3 Market size and forecast, by Distribution Channel

7.4.5.3 Australia

7.4.5.3.1 Market size and forecast, by Drug Class

7.4.5.3.2 Market size and forecast, by Gender

7.4.5.3.3 Market size and forecast, by Distribution Channel

7.4.5.4 India

7.4.5.4.1 Market size and forecast, by Drug Class

7.4.5.4.2 Market size and forecast, by Gender

7.4.5.4.3 Market size and forecast, by Distribution Channel

7.4.5.5 South Korea

7.4.5.5.1 Market size and forecast, by Drug Class

7.4.5.5.2 Market size and forecast, by Gender

7.4.5.5.3 Market size and forecast, by Distribution Channel

7.4.5.6 Rest of Asia-Pacific

7.4.5.6.1 Market size and forecast, by Drug Class

7.4.5.6.2 Market size and forecast, by Gender

7.4.5.6.3 Market size and forecast, by Distribution Channel

7.5 LAMEA

7.5.1 Key trends and opportunities

7.5.2 LAMEA Market size and forecast, by Drug Class

7.5.3 LAMEA Market size and forecast, by Gender

7.5.3.1 LAMEA Male Chronic Hepatitis B (CHB) Market by Age Group

7.5.3.2 LAMEA Female Chronic Hepatitis B (CHB) Market by Age Group

7.5.4 LAMEA Market size and forecast, by Distribution Channel

7.5.5 LAMEA Market size and forecast, by country

7.5.5.1 Brazil

7.5.5.1.1 Market size and forecast, by Drug Class

7.5.5.1.2 Market size and forecast, by Gender

7.5.5.1.3 Market size and forecast, by Distribution Channel

7.5.5.2 Saudi Arabia

7.5.5.2.1 Market size and forecast, by Drug Class

7.5.5.2.2 Market size and forecast, by Gender

7.5.5.2.3 Market size and forecast, by Distribution Channel

7.5.5.3 South Africa

7.5.5.3.1 Market size and forecast, by Drug Class

7.5.5.3.2 Market size and forecast, by Gender

7.5.5.3.3 Market size and forecast, by Distribution Channel

7.5.5.4 Rest of LAMEA

7.5.5.4.1 Market size and forecast, by Drug Class

7.5.5.4.2 Market size and forecast, by Gender

7.5.5.4.3 Market size and forecast, by Distribution Channel

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Key developments

9.1 GlaxoSmithKline (GSK)

9.1.1 Company overview

9.1.2 Company snapshot

9.1.3 Operating business segments

9.1.4 Product portfolio

9.1.5 Business performance

9.1.6 Key strategic moves and developments

9.2 Gilead Sciences, Inc.

9.2.1 Company overview

9.2.2 Company snapshot

9.2.3 Operating business segments

9.2.4 Product portfolio

9.2.5 Business performance

9.2.6 Key strategic moves and developments

9.3 Merck & Co. Inc.

9.3.1 Company overview

9.3.2 Company snapshot

9.3.3 Operating business segments

9.3.4 Product portfolio

9.3.5 Business performance

9.3.6 Key strategic moves and developments

9.4 Bristol Myers Squibb Co.

9.4.1 Company overview

9.4.2 Company snapshot

9.4.3 Operating business segments

9.4.4 Product portfolio

9.4.5 Business performance

9.4.6 Key strategic moves and developments

9.5 Teva Pharmaceutical Industries Limited

9.5.1 Company overview

9.5.2 Company snapshot

9.5.3 Operating business segments

9.5.4 Product portfolio

9.5.5 Business performance

9.5.6 Key strategic moves and developments

9.6 zydus cadila

9.6.1 Company overview

9.6.2 Company snapshot

9.6.3 Operating business segments

9.6.4 Product portfolio

9.6.5 Business performance

9.6.6 Key strategic moves and developments

9.7 Novartis AG

9.7.1 Company overview

9.7.2 Company snapshot

9.7.3 Operating business segments

9.7.4 Product portfolio

9.7.5 Business performance

9.7.6 Key strategic moves and developments

9.8 F. Hoffman La Roche, Ltd.

9.8.1 Company overview

9.8.2 Company snapshot

9.8.3 Operating business segments

9.8.4 Product portfolio

9.8.5 Business performance

9.8.6 Key strategic moves and developments

9.9 Viatris Inc. (Mylan NV)

9.9.1 Company overview

9.9.2 Company snapshot

9.9.3 Operating business segments

9.9.4 Product portfolio

9.9.5 Business performance

9.9.6 Key strategic moves and developments

9.10 Cipla Ltd

9.10.1 Company overview

9.10.2 Company snapshot

9.10.3 Operating business segments

9.10.4 Product portfolio

9.10.5 Business performance

9.10.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 2. CHRONIC HEPATITIS B (CHB) MARKET, FOR ANTIVIRALS, BY REGION, 2021-2031 ($MILLION)

TABLE 3. CHRONIC HEPATITIS B (CHB) MARKET FOR ANTIVIRALS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 4. CHRONIC HEPATITIS B (CHB) MARKET, FOR IMMUNE MODULATORS, BY REGION, 2021-2031 ($MILLION)

TABLE 5. CHRONIC HEPATITIS B (CHB) MARKET FOR IMMUNE MODULATORS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 6. GLOBAL CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)

TABLE 7. CHRONIC HEPATITIS B (CHB) MARKET, FOR MALE, BY REGION, 2021-2031 ($MILLION)

TABLE 8. CHRONIC HEPATITIS B (CHB) MARKET FOR MALE, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 9. GLOBAL MALE CHRONIC HEPATITIS B (CHB) MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 10. CHRONIC HEPATITIS B (CHB) MARKET, FOR ADULT, BY REGION, 2021-2031 ($MILLION)

TABLE 11. CHRONIC HEPATITIS B (CHB) MARKET, FOR GERIARTIC, BY REGION, 2021-2031 ($MILLION)

TABLE 12. CHRONIC HEPATITIS B (CHB) MARKET, FOR FEMALE, BY REGION, 2021-2031 ($MILLION)

TABLE 13. CHRONIC HEPATITIS B (CHB) MARKET FOR FEMALE, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 14. GLOBAL FEMALE CHRONIC HEPATITIS B (CHB) MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 15. CHRONIC HEPATITIS B (CHB) MARKET, FOR ADULT, BY REGION, 2021-2031 ($MILLION)

TABLE 16. CHRONIC HEPATITIS B (CHB) MARKET, FOR GERIARTIC, BY REGION, 2021-2031 ($MILLION)

TABLE 17. GLOBAL CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 18. CHRONIC HEPATITIS B (CHB) MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)

TABLE 19. CHRONIC HEPATITIS B (CHB) MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 20. CHRONIC HEPATITIS B (CHB) MARKET, FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)

TABLE 21. CHRONIC HEPATITIS B (CHB) MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 22. CHRONIC HEPATITIS B (CHB) MARKET, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)

TABLE 23. CHRONIC HEPATITIS B (CHB) MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 24. CHRONIC HEPATITIS B (CHB) MARKET, BY REGION, 2021-2031 ($MILLION)

TABLE 25. NORTH AMERICA CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 26. NORTH AMERICA CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)

TABLE 27. NORTH AMERICA MALE CHRONIC HEPATITIS B (CHB) MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 28. NORTH AMERICA FEMALE CHRONIC HEPATITIS B (CHB) MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 29. NORTH AMERICA CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 30. NORTH AMERICA CHRONIC HEPATITIS B (CHB) MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 31. U.S. CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 32. U.S. CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)

TABLE 33. U.S. CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 34. CANADA CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 35. CANADA CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)

TABLE 36. CANADA CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 37. MEXICO CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 38. MEXICO CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)

TABLE 39. MEXICO CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 40. EUROPE CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 41. EUROPE CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)

TABLE 42. EUROPE MALE CHRONIC HEPATITIS B (CHB) MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 43. EUROPE FEMALE CHRONIC HEPATITIS B (CHB) MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 44. EUROPE CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 45. EUROPE CHRONIC HEPATITIS B (CHB) MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 46. GERMANY CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 47. GERMANY CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)

TABLE 48. GERMANY CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 49. FRANCE CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 50. FRANCE CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)

TABLE 51. FRANCE CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 52. UK CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 53. UK CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)

TABLE 54. UK CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 55. ITALY CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 56. ITALY CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)

TABLE 57. ITALY CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 58. SPAIN CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 59. SPAIN CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)

TABLE 60. SPAIN CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 61. REST OF EUROPE CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 62. REST OF EUROPE CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)

TABLE 63. REST OF EUROPE CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 64. ASIA-PACIFIC CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 65. ASIA-PACIFIC CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)

TABLE 66. ASIA-PACIFIC MALE CHRONIC HEPATITIS B (CHB) MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 67. ASIA-PACIFIC FEMALE CHRONIC HEPATITIS B (CHB) MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 68. ASIA-PACIFIC CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 69. ASIA-PACIFIC CHRONIC HEPATITIS B (CHB) MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 70. JAPAN CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 71. JAPAN CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)

TABLE 72. JAPAN CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 73. CHINA CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 74. CHINA CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)

TABLE 75. CHINA CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 76. AUSTRALIA CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 77. AUSTRALIA CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)

TABLE 78. AUSTRALIA CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 79. INDIA CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 80. INDIA CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)

TABLE 81. INDIA CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 82. SOUTH KOREA CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 83. SOUTH KOREA CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)

TABLE 84. SOUTH KOREA CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 85. REST OF ASIA-PACIFIC CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 86. REST OF ASIA-PACIFIC CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)

TABLE 87. REST OF ASIA-PACIFIC CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 88. LAMEA CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 89. LAMEA CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)

TABLE 90. LAMEA MALE CHRONIC HEPATITIS B (CHB) MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 91. LAMEA FEMALE CHRONIC HEPATITIS B (CHB) MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 92. LAMEA CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 93. LAMEA CHRONIC HEPATITIS B (CHB) MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 94. BRAZIL CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 95. BRAZIL CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)

TABLE 96. BRAZIL CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 97. SAUDI ARABIA CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 98. SAUDI ARABIA CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)

TABLE 99. SAUDI ARABIA CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 100. SOUTH AFRICA CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 101. SOUTH AFRICA CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)

TABLE 102. SOUTH AFRICA CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 103. REST OF LAMEA CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 104. REST OF LAMEA CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)

TABLE 105. REST OF LAMEA CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 106.GLAXOSMITHKLINE (GSK): COMPANY SNAPSHOT

TABLE 107.GLAXOSMITHKLINE (GSK): OPERATING SEGMENTS

TABLE 108.GLAXOSMITHKLINE (GSK): PRODUCT PORTFOLIO

TABLE 109.GLAXOSMITHKLINE (GSK): NET SALES,

TABLE 110.GLAXOSMITHKLINE (GSK): KEY STRATERGIES

TABLE 111.GILEAD SCIENCES, INC.: COMPANY SNAPSHOT

TABLE 112.GILEAD SCIENCES, INC.: OPERATING SEGMENTS

TABLE 113.GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO

TABLE 114.GILEAD SCIENCES, INC.: NET SALES,

TABLE 115.GILEAD SCIENCES, INC.: KEY STRATERGIES

TABLE 116.MERCK & CO. INC.: COMPANY SNAPSHOT

TABLE 117.MERCK & CO. INC.: OPERATING SEGMENTS

TABLE 118.MERCK & CO. INC.: PRODUCT PORTFOLIO

TABLE 119.MERCK & CO. INC.: NET SALES,

TABLE 120.MERCK & CO. INC.: KEY STRATERGIES

TABLE 121.BRISTOL MYERS SQUIBB CO.: COMPANY SNAPSHOT

TABLE 122.BRISTOL MYERS SQUIBB CO.: OPERATING SEGMENTS

TABLE 123.BRISTOL MYERS SQUIBB CO.: PRODUCT PORTFOLIO

TABLE 124.BRISTOL MYERS SQUIBB CO.: NET SALES,

TABLE 125.BRISTOL MYERS SQUIBB CO.: KEY STRATERGIES

TABLE 126.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT

TABLE 127.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING SEGMENTS

TABLE 128.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO

TABLE 129.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES,

TABLE 130.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES

TABLE 131.ZYDUS CADILA: COMPANY SNAPSHOT

TABLE 132.ZYDUS CADILA: OPERATING SEGMENTS

TABLE 133.ZYDUS CADILA: PRODUCT PORTFOLIO

TABLE 134.ZYDUS CADILA: NET SALES,

TABLE 135.ZYDUS CADILA: KEY STRATERGIES

TABLE 136.NOVARTIS AG: COMPANY SNAPSHOT

TABLE 137.NOVARTIS AG: OPERATING SEGMENTS

TABLE 138.NOVARTIS AG: PRODUCT PORTFOLIO

TABLE 139.NOVARTIS AG: NET SALES,

TABLE 140.NOVARTIS AG: KEY STRATERGIES

TABLE 141.F. HOFFMAN LA ROCHE, LTD.: COMPANY SNAPSHOT

TABLE 142.F. HOFFMAN LA ROCHE, LTD.: OPERATING SEGMENTS

TABLE 143.F. HOFFMAN LA ROCHE, LTD.: PRODUCT PORTFOLIO

TABLE 144.F. HOFFMAN LA ROCHE, LTD.: NET SALES,

TABLE 145.F. HOFFMAN LA ROCHE, LTD.: KEY STRATERGIES

TABLE 146.VIATRIS INC. (MYLAN NV): COMPANY SNAPSHOT

TABLE 147.VIATRIS INC. (MYLAN NV): OPERATING SEGMENTS

TABLE 148.VIATRIS INC. (MYLAN NV): PRODUCT PORTFOLIO

TABLE 149.VIATRIS INC. (MYLAN NV): NET SALES,

TABLE 150.VIATRIS INC. (MYLAN NV): KEY STRATERGIES

TABLE 151.CIPLA LTD: COMPANY SNAPSHOT

TABLE 152.CIPLA LTD: OPERATING SEGMENTS

TABLE 153.CIPLA LTD: PRODUCT PORTFOLIO

TABLE 154.CIPLA LTD: NET SALES,

TABLE 155.CIPLA LTD: KEY STRATERGIES LIST OF FIGURES

FIGURE 1.CHRONIC HEPATITIS B (CHB) MARKET SEGMENTATION

FIGURE 2.CHRONIC HEPATITIS B (CHB) MARKET,2021-2031

FIGURE 3.CHRONIC HEPATITIS B (CHB) MARKET,2021-2031

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.CHRONIC HEPATITIS B (CHB) MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 12.CHRONIC HEPATITIS B (CHB) MARKET,BY DRUG CLASS,2021(%)

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ANTIVIRALS CHRONIC HEPATITIS B (CHB) MARKET,2021-2031(%)

FIGURE 14.COMPARATIVE SHARE ANALYSIS OF IMMUNE MODULATORS CHRONIC HEPATITIS B (CHB) MARKET,2021-2031(%)

FIGURE 15.CHRONIC HEPATITIS B (CHB) MARKET,BY GENDER,2021(%)

FIGURE 16.COMPARATIVE SHARE ANALYSIS OF MALE CHRONIC HEPATITIS B (CHB) MARKET,2021-2031(%)

FIGURE 17.COMPARATIVE SHARE ANALYSIS OF FEMALE CHRONIC HEPATITIS B (CHB) MARKET,2021-2031(%)

FIGURE 18.CHRONIC HEPATITIS B (CHB) MARKET,BY DISTRIBUTION CHANNEL,2021(%)

FIGURE 19.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES CHRONIC HEPATITIS B (CHB) MARKET,2021-2031(%)

FIGURE 20.COMPARATIVE SHARE ANALYSIS OF DRUG STORES AND RETAIL PHARMACIES CHRONIC HEPATITIS B (CHB) MARKET,2021-2031(%)

FIGURE 21.COMPARATIVE SHARE ANALYSIS OF ONLINE PROVIDERS CHRONIC HEPATITIS B (CHB) MARKET,2021-2031(%)

FIGURE 22.CHRONIC HEPATITIS B (CHB) MARKET BY REGION,2021

FIGURE 23.U.S. CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)

FIGURE 24.CANADA CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)

FIGURE 25.MEXICO CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)

FIGURE 26.GERMANY CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)

FIGURE 27.FRANCE CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)

FIGURE 28.UK CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)

FIGURE 29.ITALY CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)

FIGURE 30.SPAIN CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)

FIGURE 31.REST OF EUROPE CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)

FIGURE 32.JAPAN CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)

FIGURE 33.CHINA CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)

FIGURE 34.AUSTRALIA CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)

FIGURE 35.INDIA CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)

FIGURE 36.SOUTH KOREA CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)

FIGURE 37.REST OF ASIA-PACIFIC CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)

FIGURE 38.BRAZIL CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)

FIGURE 39.SAUDI ARABIA CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)

FIGURE 40.SOUTH AFRICA CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)

FIGURE 41.REST OF LAMEA CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)

FIGURE 42. TOP WINNING STRATEGIES, BY YEAR

FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 45.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 46.COMPETITIVE DASHBOARD

FIGURE 47.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 48.GLAXOSMITHKLINE (GSK).: NET SALES ,($MILLION)

FIGURE 49.GILEAD SCIENCES, INC..: NET SALES ,($MILLION)

FIGURE 50.MERCK & CO. INC..: NET SALES ,($MILLION)

FIGURE 51.BRISTOL MYERS SQUIBB CO..: NET SALES ,($MILLION)

FIGURE 52.TEVA PHARMACEUTICAL INDUSTRIES LIMITED.: NET SALES ,($MILLION)

FIGURE 53.ZYDUS CADILA.: NET SALES ,($MILLION)

FIGURE 54.NOVARTIS AG.: NET SALES ,($MILLION)

FIGURE 55.F. HOFFMAN LA ROCHE, LTD..: NET SALES ,($MILLION)

FIGURE 56.VIATRIS INC. (MYLAN NV).: NET SALES ,($MILLION)

FIGURE 57.CIPLA LTD.: NET SALES ,($MILLION